Lords Mark Industries has successfully concluded its investor conference call, which was scheduled for September 10, 2026. The event was organized by Financial Mindss, a part of the JaiBharti Group, to discuss the company’s business progress and operational developments.

The meeting took place at 4:00 pm IST via virtual audio-visual means. In compliance with Regulation 30 and Regulation 46 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company confirmed that the proceedings were recorded.

Event Details

The audio and video recordings of the investor call have been uploaded to the company's website for public access. This disclosure supersedes the earlier intimation regarding the scheduled meeting.

Regulatory Disclosure

The company made this disclosure pursuant to SEBI LODR regulations. No specific financial results or operational metrics were disclosed in this filing. The meeting may be subject to cancellation or rescheduling due to exigencies involving analysts, investors, or company officials, as noted in prior communications.

Lords Mark Industries entered a strategic collaboration with ARKALL Holdings Limited on August 24, 2026, to expand its healthcare footprint across the Caribbean region. The partnership focuses on establishing pathology laboratories and commercializing medical devices, diagnostics, and equipment.

The agreement marks the company’s entry into the Caribbean market through a phased expansion model. Initial operations will commence in Trinidad & Tobago, with progressive extension to other markets over the next three years. Lords Mark will supply IVD products, rapid test kits, biochemistry reagents, dialysis machines, and technical support, while ARKALL leads commercialization and market development.

Financial Projections

Based on internal management assessments, the phased rollout has the potential to generate approximately US$100 million in export revenue between FY27 and FY31. This projection is subject to successful implementation, regulatory approvals, and market penetration. The company estimates the indicative pathology and diagnostics opportunity across the identified Caribbean markets at approximately US$1.24 billion.

These figures represent forward-looking statements. Actual results may vary materially depending on business conditions, regulatory factors, and execution pace.

Deal Structure

ARKALL Holdings Limited will undertake 100% of the investments required for the Caribbean expansion, including scaling laboratory operations. Lords Mark provides product supply, training, and operational guidance without capital outlay for this specific venture.

Dr. Sachidanand Upadhyay, Managing Director & CEO of Lords Mark Industries, stated that the collaboration combines the company’s medical technology capabilities with ARKALL’s regional commercial presence. He described the partnership as a long-term platform for expanding export footprints while contributing to accessible healthcare infrastructure.

What the Numbers Show

The deal structure isolates capital expenditure risk for Lords Mark Industries. By securing a partner willing to fund 100% of the expansion costs while targeting US$100 million in revenue over five years, the company positions itself for high-margin export growth without immediate balance sheet impact. The disparity between the US$100 million revenue projection and the US$1.24 billion total market opportunity suggests significant room for share acquisition, contingent on execution speed against competitors.